Evidence map›Paper›PMID 34636650›Full record

ArticleCirculation2021

Interferon-γ Impairs Human Coronary Artery Endothelial Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid Oxidation.

Laurel Yong-Hwa Lee, William M Oldham, Huamei He, Ruisheng Wang, Ryan Mulhern, Diane E Handy, Joseph Loscalzo

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  12. Review
  13. Roles of the Altitude-Adapted Immune Microenvironment in Pulmonary Vascular Remodeling in High-Altitude Pulmonary Hypertension: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Laurel Yong-Hwa LeeDivision of Cardiovascular Medicine (L.Y.-H.L., H.H., R.W., R.M., D.E.H., J.L.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-2161-5966
William M OldhamDivision of Pulmonary and Critical Care (W.M.O.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0003-3029-4866
Huamei HeDivision of Cardiovascular Medicine (L.Y.-H.L., H.H., R.W., R.M., D.E.H., J.L.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Ruisheng WangDivision of Cardiovascular Medicine (L.Y.-H.L., H.H., R.W., R.M., D.E.H., J.L.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Ryan MulhernDivision of Cardiovascular Medicine (L.Y.-H.L., H.H., R.W., R.M., D.E.H., J.L.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Diane E HandyDivision of Cardiovascular Medicine (L.Y.-H.L., H.H., R.W., R.M., D.E.H., J.L.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Joseph LoscalzoDivision of Cardiovascular Medicine (L.Y.-H.L., H.H., R.W., R.M., D.E.H., J.L.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-1153-8047
Brigham and Women's Hospital · US

Funding

Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
Center for Integrated Approaches to Undiagnosed DiseasesU01HG007690 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2014 to 2022
$10.4M
L-2-Hydroxyglutarate and Metabolic Remodeling in HypoxiaR01HL155107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Joseph Loscalzo · 2021 to 2026
$4.1M
The Phathophenotype Landscape of Complex DiseaseU01HL108630 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2011 to 2014
$2.7M
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertensionR01HL155096 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2021 to 2024
$1.6M
Regulation of pulmonary vascular cell redox state by L-2-hydroxyglutarateK08HL128802 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI OLDHAM, WILLIAM MICHAEL · 2016 to 2020
$862k
NHGRI NIH HHS U01 HG007690NHLBI NIH HHS K08 HL128802NHLBI NIH HHS R01 HL155096NHLBI NIH HHS R01 HL155107NHLBI NIH HHS U01 HL108630NHLBI NIH HHS U54 HL119145
6 · The paper itself

Abstract

backgroundEndothelial cells depend on glycolysis for much of their energy production. Impaired endothelial glycolysis has been associated with various vascular pathobiologies, including impaired angiogenesis and atherogenesis. IFN-γ (interferon-γ)-producing CD4

methodsThe metabolic effects of IFN-γ on primary human coronary artery endothelial cells were assessed by unbiased transcriptomic and metabolomic analyses combined with real-time extracellular flux analyses and molecular mechanistic studies. Cellular phenotypic correlations were made by measuring altered endothelial intracellular cGMP content, wound-healing capacity, and adhesion molecule expression.

resultsIFN-γ exposure inhibited basal glycolysis of quiescent primary human coronary artery endothelial cells by 20% through the global transcriptional suppression of glycolytic enzymes resulting from decreased basal HIF1α (hypoxia-inducible factor 1α) nuclear availability in normoxia. The decrease in HIF1α activity was a consequence of IFN-γ-induced tryptophan catabolism resulting in ARNT (aryl hydrocarbon receptor nuclear translocator)/HIF1β sequestration by the kynurenine-activated AHR (aryl hydrocarbon receptor). In addition, IFN-γ resulted in a 23% depletion of intracellular nicotinamide adenine dinucleotide in human coronary artery endothelial cells. This altered glucose metabolism was met with concomitant activation of fatty acid oxidation, which augmented its contribution to intracellular ATP balance by >20%. These metabolic derangements were associated with adverse endothelial phenotypic changes, including decreased basal intracellular cGMP, impaired endothelial migration, and a switch to a proinflammatory state.

conclusionsIFN-γ impairs endothelial glucose metabolism by altered tryptophan catabolism destabilizing HIF1, depletes nicotinamide adenine dinucleotide, and results in a metabolic shift toward increased fatty acid oxidation. This work suggests a novel mechanistic basis for pathological T lymphocyte-endothelial interactions in atherosclerosis mediated by IFN-γ, linking endothelial glucose, tryptophan, and fatty acid metabolism with the nicotinamide adenine dinucleotide balance and ATP generation and their adverse endothelial functional consequences.

Indexed as

Energy MetabolismBiomarkersCell MovementCell ProliferationCells, CulturedCoronary VesselsEndothelial CellsFatty AcidsGene Expression RegulationGlucoseGlycolysisHumansHypoxia-Inducible Factor 1, alpha SubunitInterferon-gammaKynurenineOxidation-ReductionBiomarkersFatty AcidsGlucoseHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitInterferon-gammaKynurenineTryptophancoronary arteryendotheliumfatty acid oxidationglycolysisinterferon-γmetabolismtryptophan

Identifiers

PMID34636650
PMCPMC8595869
OpenAlexW3206675933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.